BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 431 filers reported holding BIO-TECHNE CORP in Q4 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,676 | -3.6% | 54,000 | +15.6% | 0.10% | +1.0% |
| Q2 2023 | $3,812 | +10.0% | 46,700 | 0.0% | 0.10% | +6.4% |
| Q1 2023 | $3,465 | -10.5% | 46,700 | 0.0% | 0.09% | -13.0% |
| Q4 2022 | $3,870 | -99.9% | 46,700 | +300.0% | 0.11% | +9.1% |
| Q3 2022 | $3,316,000 | -18.1% | 11,675 | 0.0% | 0.10% | -19.5% |
| Q2 2022 | $4,047,000 | -20.0% | 11,675 | 0.0% | 0.12% | -9.6% |
| Q1 2022 | $5,056,000 | -9.7% | 11,675 | +7.9% | 0.14% | +3.0% |
| Q4 2021 | $5,600,000 | +47.0% | 10,825 | +37.7% | 0.13% | +33.3% |
| Q3 2021 | $3,809,000 | +7.6% | 7,860 | 0.0% | 0.10% | +12.5% |
| Q2 2021 | $3,539,000 | +17.3% | 7,860 | -0.5% | 0.09% | +11.4% |
| Q1 2021 | $3,017,000 | +48.5% | 7,900 | +23.4% | 0.08% | +43.6% |
| Q4 2020 | $2,032,000 | -19.3% | 6,400 | -43.5% | 0.06% | +44.7% |
| Q3 2020 | $2,519,000 | +73.5% | 11,325 | +105.9% | 0.04% | -17.4% |
| Q2 2020 | $1,452,000 | +39.2% | 5,500 | 0.0% | 0.05% | +17.9% |
| Q1 2020 | $1,043,000 | -13.6% | 5,500 | 0.0% | 0.04% | +14.7% |
| Q4 2019 | $1,207,000 | +12.2% | 5,500 | 0.0% | 0.03% | +3.0% |
| Q3 2019 | $1,076,000 | -15.7% | 5,500 | -10.2% | 0.03% | -15.4% |
| Q2 2019 | $1,277,000 | +5.0% | 6,125 | 0.0% | 0.04% | +2.6% |
| Q1 2019 | $1,216,000 | +37.2% | 6,125 | 0.0% | 0.04% | +31.0% |
| Q4 2018 | $886,000 | -29.1% | 6,125 | 0.0% | 0.03% | -9.4% |
| Q3 2018 | $1,250,000 | +16.9% | 6,125 | -15.2% | 0.03% | +14.3% |
| Q2 2018 | $1,069,000 | -2.0% | 7,225 | 0.0% | 0.03% | +3.7% |
| Q1 2018 | $1,091,000 | +16.6% | 7,225 | 0.0% | 0.03% | +22.7% |
| Q4 2017 | $936,000 | +7.2% | 7,225 | 0.0% | 0.02% | 0.0% |
| Q3 2017 | $873,000 | -0.6% | 7,225 | -3.3% | 0.02% | 0.0% |
| Q2 2017 | $878,000 | +13.3% | 7,475 | -2.0% | 0.02% | +15.8% |
| Q1 2017 | $775,000 | -14.1% | 7,625 | -13.1% | 0.02% | -20.8% |
| Q4 2016 | $902,000 | -6.1% | 8,775 | 0.0% | 0.02% | -4.0% |
| Q3 2016 | $961,000 | -2.9% | 8,775 | 0.0% | 0.02% | -3.8% |
| Q2 2016 | $990,000 | +19.4% | 8,775 | 0.0% | 0.03% | +73.3% |
| Q1 2016 | $829,000 | +4.9% | 8,775 | 0.0% | 0.02% | 0.0% |
| Q4 2015 | $790,000 | -2.6% | 8,775 | 0.0% | 0.02% | 0.0% |
| Q3 2015 | $811,000 | -6.1% | 8,775 | 0.0% | 0.02% | -6.2% |
| Q2 2015 | $864,000 | -1.8% | 8,775 | 0.0% | 0.02% | +6.7% |
| Q1 2015 | $880,000 | -35.1% | 8,775 | -40.2% | 0.02% | -34.8% |
| Q4 2014 | $1,356,000 | – | 14,675 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
| Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
| STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
| DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
| Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
| MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
| Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
| GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
| Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
| CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |